載入中
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
一般交易時段
US$8.23
−US$0.58 · -6.58%
盤中時間採用ET。市場資料可能有所延遲。
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
日內區間
目前US$8.23
52週區間
目前US$8.23
盤中時間採用ET。市場資料可能有所延遲。
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
日內區間
目前US$8.23
52週區間
目前US$8.23
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（AUD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4.2萬 AUD | 230.8萬 AUD | 555 AUD | 1萬 AUD | 1518.3萬 AUD |
| 毛利 | 4.2萬 AUD | 230.8萬 AUD | 555 AUD | 1萬 AUD | 1518.3萬 AUD |
| 研究與開發 | 732.6萬 AUD | 1738萬 AUD | 1556.41萬 AUD | 2016.9萬 AUD | 1454.1萬 AUD |
| 銷售、一般及管理費用 | 872萬 AUD | 1356.3萬 AUD | 858.3萬 AUD | 524萬 AUD | 702萬 AUD |
| 營業費用 | 1425.9萬 AUD | 3077萬 AUD | 2412.45萬 AUD | 2540.9萬 AUD | 2155.9萬 AUD |
| 利息收入 | 7.2萬 AUD | 1.2萬 AUD | 2.28萬 AUD | 2094 AUD | 4.22萬 AUD |
| 利息支出 | — | — | — | 2094 AUD | — |
| 折舊和攤銷 | 93.4萬 AUD | 186.9萬 AUD | 186.9萬 AUD | 186.9萬 AUD | 126.5萬 AUD |
| 營業利益 | −1421.7萬 AUD | −2846.2萬 AUD | −2412.4萬 AUD | −2539.9萬 AUD | −637.6萬 AUD |
| 淨利 | −2070.2萬 AUD | −2677.8萬 AUD | −2046.52萬 AUD | −2501.4萬 AUD | −842萬 AUD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年4月17日 | 1:5 | — | — |
股票分割 | 2024年10月28日 | 1:10 | — | — |
股票分割 | 2020年10月2日 | 1,041:1,000 | — | — |
股票分割 | 2017年7月14日 | 1:4 | — | — |
股票分割 | 2013年1月28日 | 1,519:500 | — | — |
股票分割 | 2012年1月3日 | 1:5 | — | — |
已生效 2025年4月17日
1:5
已生效 2024年10月28日
1:10
已生效 2020年10月2日
1,041:1,000
已生效 2017年7月14日
1:4
已生效 2013年1月28日
1,519:500
已生效 2012年1月3日
1:5
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
